← Back to Home

Extending Evidence from Carcinoma in Situ: FDA Expands Anktiva Approval to Certain Papillary Bladder Cancers

Patients with high-grade papillary tumors only now have a newly approved option after BCG treatment fails. The FDA supported this expanded indication with efficacy evidence from a similar disease subtype, establishing a path for extrapolating evidence in bladder cancer drug development.

By SURL BioNews

Bladder cancer that has not invaded the muscle layer can still pose a threat of recurrence and progression. For patients whose disease remains uncontrolled after treatment with bacillus Calmette-Guérin (BCG), the U.S. Food and Drug Administration (FDA) expanded the indication for Anktiva in combination with BCG on October 14, 2026, to include adults with non-muscle-invasive bladder cancer with high-grade papillary tumors only, without carcinoma in situ.

According to the FDA announcement, this is the first therapy specifically approved for this population. Anktiva was originally approved for BCG-unresponsive disease involving carcinoma in situ (CIS), with or without papillary tumors; this expansion extends treatment to papillary disease without CIS. Central to the review was the FDA's determination that the scientific similarities between the two disease subtypes were sufficient to support extrapolation of the existing efficacy evidence.

The two subtypes grow differently within the bladder: CIS forms flat lesions along the inner lining, while papillary tumors grow into the bladder cavity as small, fingerlike projections. However, the FDA noted that high-grade papillary tumors and CIS are both aggressive urothelial cancers, frequently coexist, and can sometimes be difficult to distinguish pathologically. Both also carry a high risk of recurrence and progression after BCG fails. Overlapping clinical and nonclinical characteristics formed the basis for this expanded approval.

Cohort A of the QUILT-3.032 study, which supported the original approval, was a multicenter, single-arm trial involving 77 patients, all of whom had CIS, with some also having papillary lesions. The complete response rate with Anktiva plus BCG was 62%; among those who achieved a complete response, 58% maintained their response for at least 12 months and 40% for at least 24 months. Here, a complete response means that examinations detected no high-grade cancer and cannot be directly interpreted as a cure. These percentages are also not direct efficacy results for the newly added papillary-only population.

Treatment involves instilling Anktiva and BCG into the bladder through a catheter to fight cancer through immune activity. Common adverse reactions include painful urination, frequent urination, blood in the urine, urinary tract infection, and fever. Elevated creatinine or blood potassium levels may also occur. The prescribing information also contains an explicit warning: delaying cystectomy may allow the cancer to develop into metastatic disease that can be fatal. The additional treatment option still requires assessment of the risks when disease persists or worsens.

This decision will also affect how evidence is presented for future drugs. The FDA is advancing the finalization of related drug development guidance, which is expected to discuss how studies in patients with CIS could support approval for high-grade papillary-only disease. However, the guidance has not yet been finalized. This approval rests on similarities between specific disease subtypes, and a single-arm study cannot directly establish how the therapy compares with other treatments. Expanding the population eligible for treatment and clarifying long-term benefits remain two questions that need to be assessed separately.

References

  1. FDA
  2. FDA